Free Trial
NYSE:MED

Medifast (MED) Stock Price, News & Analysis

Medifast logo
$18.14 -0.14 (-0.77%)
(As of 11/15/2024 ET)

About Medifast Stock (NYSE:MED)

Key Stats

Today's Range
$18.08
$18.59
50-Day Range
$17.31
$20.44
52-Week Range
$17.07
$76.42
Volume
145,705 shs
Average Volume
191,551 shs
Market Capitalization
$198.45 million
P/E Ratio
27.48
Dividend Yield
N/A
Price Target
$17.00
Consensus Rating
Hold

Company Overview

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

Medifast Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
52nd Percentile Overall Score

MED MarketRank™: 

Medifast scored higher than 52% of companies evaluated by MarketBeat, and ranked 94th out of 143 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Medifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Medifast has only been the subject of 1 research reports in the past 90 days.

  • Read more about Medifast's stock forecast and price target.
  • Earnings Growth

    Earnings for Medifast are expected to decrease by -38.41% in the coming year, from $1.51 to $0.93 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Medifast is 27.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.01.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Medifast is 27.48, which means that it is trading at a more expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 20.70.

  • Price to Book Value per Share Ratio

    Medifast has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Medifast's valuation and earnings.
  • Percentage of Shares Shorted

    15.55% of the float of Medifast has been sold short.
  • Short Interest Ratio / Days to Cover

    Medifast has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Medifast has recently decreased by 6.78%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Medifast does not currently pay a dividend.

  • Dividend Growth

    Medifast does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.55% of the float of Medifast has been sold short.
  • Short Interest Ratio / Days to Cover

    Medifast has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Medifast has recently decreased by 6.78%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Medifast has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Consumer Staples companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Medifast this week, compared to 4 articles on an average week.
  • Search Interest

    Only 3 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Medifast insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.50% of the stock of Medifast is held by insiders.

  • Percentage Held by Institutions

    95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Medifast's insider trading history.
Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

MED Stock News Headlines

Medifast Faces Revenue Decline Amid Strategic Adjustments
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Medifast reports Q3 EPS 10c vs $2.12 last year
Medifast upgraded to Neutral from Underperform at DA Davidson
DA Davidson Upgrades Medifast (MED)
See More Headlines

MED Stock Analysis - Frequently Asked Questions

Medifast's stock was trading at $67.22 at the beginning of 2024. Since then, MED stock has decreased by 73.0% and is now trading at $18.14.
View the best growth stocks for 2024 here
.

Medifast, Inc. (NYSE:MED) issued its quarterly earnings data on Monday, November, 4th. The specialty retailer reported $0.35 EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.50. The specialty retailer had revenue of $140.16 million for the quarter, compared to the consensus estimate of $135.45 million. Medifast had a net margin of 1.09% and a trailing twelve-month return on equity of 15.98%.

Top institutional investors of Medifast include Hotchkis & Wiley Capital Management LLC (2.70%), Geode Capital Management LLC (2.23%), State Street Corp (1.98%) and Jacobs Levy Equity Management Inc. (1.55%). Insiders that own company stock include Daniel R Chard, Scott Schlackman, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist.
View institutional ownership trends
.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY).

Company Calendar

Last Earnings
11/04/2024
Today
11/17/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/18/2025

Industry, Sector and Symbol

Industry
Miscellaneous food preparations & kindred products
Sub-Industry
Personal Products
CUSIP
58470H10
Employees
870
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$17.00
Low Stock Price Target
$17.00
Potential Upside/Downside
-6.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$99.42 million
Pretax Margin
1.83%

Debt

Sales & Book Value

Annual Sales
$1.07 billion
Cash Flow
$10.86 per share
Book Value
$18.96 per share

Miscellaneous

Free Float
10,665,000
Market Cap
$198.45 million
Optionable
Optionable
Beta
1.13

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NYSE:MED) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners